Braeden William Lichti: The Business of Anti-Aging and Rejuvenation Biotechnology
Washingtoner/10147573

VANCOUVER, British Columbia - Washingtoner -- 2020-07-30: Scientists now have a better understanding into the aging process, giving us a better explanation of the cellular changes that lead our body and brain to decline as we age. Many believe that inflammation, stress, diet, exercise, and genetics greatly contribute to our aging process.

New studies are pointing to promising treatments that could slow, stop, or even reverse the signs of aging. This isn't just about turning back the clock in order to have a longer life span, it's about extending our healthy years.

In one study, mice were given pills that mimicked the positive benefits of exercise. If it works in mice would it be effective in humans? And what does this portend for the future, if our lifespan increases and we all live decades longer?

The business of anti-aging and rejuvenation is gaining steam and should be on the radar of investors — the Bank of America has forecasted that the market will balloon from $110 billion today, to nearly to $610 billion by 2025.

More on Washingtoner

• DuoKey Launches Quantum Risk Score to Help Enterprises Prioritise Post-Quantum Cryptography Migration
• Top 5 Most Reliable Used Vans in the UK in 2026
• Dominican Fashion Designer Raiza Bonaparte presents the Sovereign Despampanante Collection at the Library of Congress
• Tacoma: A Statement from At-Large Council Member Latasha Palmer on Rental Housing Resolution
• Tacoma City Council Adopts Six-Year Transportation Improvement Program

Researchers have jumped on this trend too. In 2012, only 73 trials were conducted to reverse aging and that number doubled by the end of 2017 to 145. In 2018, this industry accounted for the most significant amount of investment, as market participants attracted an amount close to $800M (for comparison, back in 2014, it was only about $100M). The number of investment deals is also growing, with the highest number of the past six years recorded in 2017 (25 according to CB Insights, up from 13 a year earlier).

Companies like Juvenescence have raised over $100M to advance multiple anti-aging programs. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully improve human health and extends our lifespan.

Here are additional industry developments we're excited about:

Juvenescence's portfolio currently includes Insilico Medicine, a next-generation artificial intelligence company specializing in the application of deep learning to drug discovery and aging research. Juvenescence AI, a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds.

More on Washingtoner

• Tacoma City Council Adopts 2026 Annual Code Amendments
• What Happens When Congress Says No? New Book Examines the Boland Amendments, Iran-Contra Affair & Jamaican Posse, as US Congress Debate Over Military
• Beware of Fake City of Spokane Development and Permit Invoices
• Warm, Dry Summer Forecast Points to a Stronger Wasp and Yellowjacket Season Across the Pacific Northwest
• Qscription Technologies Appoints Anurag Velekkatt Sunil Kumar to Drive Enterprise Scale

UNITY Biotechnology, a company developing therapeutics to extend healthspan with an initial focus on cellular senescence..

AgeX Therapeutics, a company applying intellectual property related to cell immortality and pluripotency.

Finding the latest developments

Investors can follow the latest advancements in anti-aging and rejuvenation by reading magazines such as Nature and The New Scientist. Both publications recently featured interesting articles that highlighted recent developments. We also recommend following websites like fiercebiotech, (https://www.fiercebiotech.com/) scientificamerican (https://www.scientificamerican.com/), and tracking IPOs (https://www.nasdaq.com/market-activity/ipos) to find other companies developing innovative technologies